Next-generation heparin antidotes: “Exosomes as a biocompatible alternative to protamine sulfate”
Molecular Biology Reports · 2026-12 · 53 (1)
DOI: 10.1007/s11033-026-12145-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biology Reports, online erschienen am 19.06.2026. Verfasst von Leyla Bahar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Health Sciences Institute, Department of Stem Cell and Regenerative Medicine, Mersin University, Çiftlikköy Campüs, Mersin, Türkiye. leylabahar@mersi…. Hauptthemen laut MEDLINE: Protamines, Heparin, Exosomes, Heparin Antagonists. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mersin University.
Abstract (Originalsprache)
Purpose
Controlling bleeding is one of the most fundamental challenges in cardiac surgery. Bleeding is controlled by neutralising heparin with protamine. Our study investigates exosomes as an alternative treatment option to protamine for use in haemostasis.
Methods
Rats were divided into 5 groups, with 4 rats in each group: Group 1 underwent puncture, Group 2 underwent heparinised puncture, Group 3 received exosomes prior to heparinised puncture, Group 4 received exosomes prior to heparinised puncture with heparin neutralised by protamine, and Group 5 received heparinised puncture with exosomes administered during puncture. Biochemical analysis was made, histopathological analysis showing tissue damage and Mast Cell Activity (MAST )in lung tissues. Western blot method for SERPINC1 expression.
Results
Despite high Activated Clotting Time levels, bleeding time was found to be shorter in the group treated with exosomes. In MAST analyses, Group 4 had the highest density, while Group 3 had a density close to that of the control group. A significant difference was detected between Groups 3 and 4. in terms of lung tissue damage ( P < 0.001). Tissue damage was most pronounced in Group 4. The application of exosomes significantly reduced inflammation and oedema in Group 3.
Conclusion
Exosomes shorten bleeding time and reduce lung tissue damage when administered before puncture. Exosomes have the potential to replace protamine in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Health Sciences Institute, Department of Stem Cell and Regenerative Medicine, Mersin University, Çiftlikköy Campüs, Mersin, Türkiye. leylabahar@mersin.edu.tr.
- Department of Cardiovascular Surgery, Health Sciences University, Mersin City Training and Research Hospital, Mersin, Türkiye.
- Onkim Stem Cell Technologies, İstanbul, Türkiye.
- Faculty of Medicine, Internal Medical Sciences, Department of Pharmacology, Mersin University, Mersin, Türkiye.
- Vocational School of Health Services, Mersin University, Mersin, Türkiye.
Förderung
- Mersin University
Zitieren
APA
Bahar, L., Tüysüz, M. E., Omay, P. H., Kınay, V., Büyükafşar, K., & Ertürk, S. E. (2026). Next-generation heparin antidotes: “Exosomes as a biocompatible alternative to protamine sulfate”. Molecular Biology Reports, 53(1). https://doi.org/10.1007/s11033-026-12145-7
Vancouver
Bahar L, Tüysüz ME, Omay PH, Kınay V, Büyükafşar K, Ertürk SE. Next-generation heparin antidotes: “Exosomes as a biocompatible alternative to protamine sulfate”. Molecular Biology Reports. 2026;53(1). doi:10.1007/s11033-026-12145-7
BibTeX
@article{Bahar2026,
author = {Bahar, Leyla and Tüysüz, Mehmet Erin and Omay, Pınar Hüner and Kınay, Vehbi and Büyükafşar, Kansu and Ertürk, Sema Erden},
title = {Next-generation heparin antidotes: “Exosomes as a biocompatible alternative to protamine sulfate”},
journal = {Molecular Biology Reports},
year = {2026},
volume = {53},
number = {1},
doi = {10.1007/s11033-026-12145-7}
}
EUVIMED